Engineered Herpes Virus for Glioblastoma Immunotherapy

A Powerful New Direction in Glioblastoma Care

Glioblastoma continues to be one of the most challenging malignancies encountered in neurology and oncology, with limited therapeutic options and high recurrence rates. Despite advances in surgery, radiotherapy, and systemic treatments, the tumor’s ability to suppress immune activity has restricted the success of many immunotherapy strategies.

Explore All Neurology and Oncology CME/CE Conferences and Online Courses

A new study from Mass General Brigham, published in Nature Cancer, is gaining notable interest among clinicians. Investigators have developed an engineered herpes virus designed to energize the immune system within the tumor microenvironment, offering a targeted and potentially more durable approach to treating glioblastoma.

How the Modified HSV-1 Reprograms the Tumor Environment

The research team modified a herpes simplex virus (HSV-1) to recognize glioblastoma-specific markers, ensuring selective targeting of malignant cells while sparing healthy neurons. This redesigned oncolytic platform delivers five immunomodulatory molecules known to influence immune activation. These include IL-12 and anti-PD1, which support T-cell revitalization; a bispecific T-cell engager that improves tumor-directed cytotoxicity; 15-hydroxyprostaglandin dehydrogenase, which helps reduce immunosuppressive signalling; and anti-TREM2, aimed at reprogramming myeloid cell populations.

The virus also carries built-in “off-switches” that minimize unintended spread within the central nervous system, strengthening its safety profile. To support clinical utility, the virus was engineered to express a PET-visible tracer protein, allowing clinicians to track its distribution and activity in real time.

Promising Preclinical Evidence of Traceable HSV-1 therapy showing potent immune responses in glioblastoma models

In preclinical glioblastoma models, a single dose of the engineered HSV-1 demonstrated significant activation of immune cells within the tumor bed. There was a marked increase in functional T-cell infiltration, enhanced NK-cell engagement, and reduced T-cell exhaustion markers, changes that collectively support more effective antitumor activity.

Mice receiving the viral therapy experienced improved survival outcomes compared with untreated controls, highlighting the therapeutic potential of this multifaceted platform.

Senior author Francisco J. Quintana, PhD, noted that this approach delivers “strong cytotoxic and immunostimulatory activities” while preserving safety, making it suitable for future translational research.

What Comes Next for Neuro-Oncology and Viral Immunotherapy?

The next step involves assessing the virus in early-phase human studies to determine dosing, safety, and therapeutic potential. Researchers also see opportunities to adapt this platform for other hard-to-treat solid tumors by reshaping their immune landscapes.

For neurologists, neurosurgeons, oncologists, and cancer researchers, this study presents a promising development in viral immunotherapy and a new direction for treating aggressive brain tumors.

Source:

Mass General Brigham